Page 1

Novavax Investor Relations - COVID - 19 vaccine candidate efficacy in those 18 to < 65 years old was preserved in influenza vaccine recipients - Influenza vaccine immunogenicity preserved - Study demonstrated no early safety concerns - Data available ahead of publication via preprint server , medRxiv GAITHERSBURG , Md . , June 14 , 2021 / PRNewswire / -- Novavax , Inc. ( Nasdaq : NVAX ) , a biotechnology company developing next - generation vaccines for serious infectious diseases , today announced data from the first co - administration study of a SARS - CoV - 2 vaccine candidate [ Novavax , NVX - CoV2373 ] and an approved influenza vaccine [ Seqirus , adjuvanted , trivalent seasonal influenza vaccine ( aTIV ) or a cell - based , quadrivalent seasonal influenza vaccine ( QIVc ) ] . The findings suggest simultaneous vaccination may be a viable immunization strategy . In addition , the protection afforded by the candidate vaccine was consistent with the main study at 87.5 % and 89.8 % respectively . A preprint of the manuscript , ' Safety , Immunogenicity , and Efficacy of a COVID - 19 Vaccine ( NVX - CoV2373 ) Co - administered With Seasonal Influenza Vaccines , ' is available at medRxiv.org and has been submitted for peer - review . As part of Novavax ' Phase 3 clinical trial of NVX - CoV2373 , its recombinant nanoparticle protein - based COVID - 19 vaccine candidate , in the United Kingdom , 431 volunteers were also enrolled in a co administration sub - study , led by researchers at St George's , University of London and St George's Hospital , London . All received an approved seasonal influenza vaccine with approximately half the participants co vaccinated with NVX - CoV2373 while the remainder received placebo . The study demonstrated that vaccine efficacy appeared to be preserved in those receiving both vaccines compared to those vaccinated with NVX CoV2373 alone . " As the next influenza season approaches and people still need a primary COVID - 19 vaccine series or a booster , separate healthcare visits to cover both COVID - 19 and influenza vaccinations will be burdensome , " said Gregory M. Glenn , M.D. , President of Research and Development , Novavax . " As the first clinical study to evaluate safety , immunogenicity , and efficacy of a COVID - 19 vaccine when co - administered with a seasonal influenza vaccine , these results demonstrate the promising opportunity for concomitant vaccination , which may improve the uptake of both vaccines . " A Favorable Safety and Reactogenicity Profile and Robust Immune Response Local and systemic reactogenicity was largely absent or mild in all groups with only a few events such as pain and tenderness at the injection site and muscle aches being elevated in those co - vaccinated . Local events generally lasted 1-2 days , while systemic events lasted approximately one day for both the co - vaccinated group and the group that received only NVX - CoV2373 . In addition to reactogenicity , participants were monitoring for unsolicited adverse events ( AES ) , medically attended AES ( MAAES ) , and serious AEs ( SAES ) . Rates of severe events were low in all groups and there were no additional early safety concerns associated with co - administration . Rates of unsolicited AES , MAAES , and SAEs were low and balanced between the groups .